Illumina, Inc. $ILMN Shares Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. boosted its holdings in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 217.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,000 shares of the life sciences company’s stock after purchasing an additional 5,478 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Illumina were worth $2,189,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in ILMN. Illinois Municipal Retirement Fund raised its stake in Illumina by 6.8% during the third quarter. Illinois Municipal Retirement Fund now owns 115,293 shares of the life sciences company’s stock valued at $31,553,000 after buying an additional 7,327 shares during the last quarter. Lido Advisors LLC boosted its holdings in Illumina by 61.5% in the third quarter. Lido Advisors LLC now owns 7,084 shares of the life sciences company’s stock worth $1,939,000 after acquiring an additional 2,698 shares in the last quarter. Keybank National Association OH grew its stake in shares of Illumina by 1.5% in the third quarter. Keybank National Association OH now owns 376,809 shares of the life sciences company’s stock worth $103,125,000 after acquiring an additional 5,682 shares during the last quarter. 71 West Capital Partners purchased a new stake in shares of Illumina in the third quarter worth $412,000. Finally, Gryphon Financial Partners LLC purchased a new stake in shares of Illumina in the third quarter worth $252,000. Institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Illumina stock opened at $207.01 on Monday. The firm has a market cap of $31.30 billion, a price-to-earnings ratio of 35.63, a PEG ratio of 2.81 and a beta of 1.46. The stock has a fifty day simple moving average of $249.02 and a two-hundred day simple moving average of $179.64. Illumina, Inc. has a 12 month low of $112.65 and a 12 month high of $309.35. The company has a current ratio of 2.63, a quick ratio of 2.05 and a debt-to-equity ratio of 0.57.

Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.26. The firm had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The company’s revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.34 earnings per share. Equities analysts predict that Illumina, Inc. will post 5.43 EPS for the current fiscal year.

Recent Illumina Headlines

Investors following ILMN have been watching these headlines:

  • Positive Sentiment: An updated valuation estimate raised Illumina’s fair value to $261.45 per share from $248.90, offering a potential upside reference. Illumina Stock Sees Modest Fair Value Lift
  • Positive Sentiment: Illumina expanded its molecular residual disease research portfolio with a duplex-sequencing workflow and was selected to provide whole-genome sequencing for Singapore’s SG-INSIGHT study, supporting its clinical oncology and precision-medicine ambitions. Illumina Unveils Duplex Sequencing Workflow for MRD Research
  • Neutral Sentiment: Chief Accounting Officer Scott Ericksen sold 267 shares under a pre-arranged Rule 10b5-1 plan, a relatively small reduction in his holdings. SEC filing

Insider Activity

In other Illumina news, CAO Scott D. Ericksen sold 267 shares of the company’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $217.76, for a total transaction of $58,141.92. Following the transaction, the chief accounting officer owned 14,029 shares in the company, valued at approximately $3,054,955.04. This represents a 1.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 98,833 shares of the company’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $216.87, for a total transaction of $21,433,912.71. Following the transaction, the director owned 208,826 shares in the company, valued at $45,288,094.62. This represents a 32.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 1,881,899 shares of company stock valued at $415,905,954 over the last quarter. 2.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several analyst reports. Leerink Partners raised their price target on Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. Argus lifted their price target on Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a research report on Thursday, September 3rd. Piper Sandler upped their price target on shares of Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, September 28th. Wall Street Zen downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. Finally, Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 1st. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, Illumina has a consensus rating of “Hold” and an average target price of $244.24.

Read Our Latest Report on ILMN

Illumina Company Profile

(Free Report)

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

See Also

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.